Biopharmaceutical company: Cymabay Therapeutics, Inc. (CBAY) (1988)

Cymabay Therapeutics, Inc. (NASDAQ: CBAY) was founded in 1988, formerly known as Metabolex, Inc., headquartered in Newark, California, USA, with 22 full-time employees. It is a biopharmaceutical company focusing on the development and commercialization of professional and orphan drugs .

Cymabay Therapeutics

Cymabay Therapeutics, Inc. (CBAY):

Cymabay Therapeutics products include:

  1. seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor δ, has completed a phase II clinical study for the treatment of primary cholangitis and homozygous familial hypercholesterolemia .
  2. arhalofenate-Five phase II clinical trials for the treatment of gout have been completed.
  3. MBX-2982-an oral G protein coupled receptor agonist for the treatment of type II diabetes.

CymaBay Therapeutics Inc. and Kowa Pharmaceuticals America, Inc. signed a license agreement to develop and commercialize arhalofenate in the United States; signed a development and license agreement with Janssen Pharmaceuticals, Inc. to develop and discover therapeutic II An undisclosed metabolic disease targeted agonist for type 2 diabetes and other diseases; signed a license and development agreement with DiaTex, Inc. to develop and commercialize haofenate, its enantiomers, derivatives and analogs Therapeutic products to treat diseases.

Notify of
Inline Feedbacks
View all Intels

Architectural product manufacturer for residential exterior walls: Ply Gem Holdings (PGEM) (2004)

Argentina’s largest food supplier: Adecoagro SA (AGRO)(2002)